Latest Period
Q1 2026
Security Snapshot
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) Institutional Ownership
CUSIP: 61225M102
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
187
Shares (Excl. Options)
86,940,802
Price
$16.45
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GLUE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 86,940,802
- Total 13F value
- $1,430,092,919
- Portfolio coverage rank
- 0.01%
- Share change
- +21,567,746
- Value change
- +$355,134,215
- Number of holders
- 187
- Shares outstanding
- 84,039,109
- SEC-reported price per share
- $18.81
- Insider filing price
- $18.81
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 61225M102.
- 187 institutions reported positions in Q1 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 160 to 187 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,011,015,664 to $1,430,092,919.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 187 institutions filings for Q1 2026.
Security key
61225M102
Latest holder period
Q1 2026
13F holders
187
13D/G owners
11
CIK / CUSIP context first
Open Q1 2026 holders
GLUE full holder history
Monte Rosa Therapeutics, Inc. SEC filings
Monte Rosa Therapeutics, Inc. company facts
Monte Rosa Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61225M102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
GLUE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 10% | +47% | $155,158,528 | +$79,195,063 | 8,876,346 | +104% | Baker Bros. Advisors LP | 31 Mar 2026 |
| New Enterprise Associates 17, L.P. | 9.7% | $143,153,471 | 7,797,030 | Ali Behbahani | 17 Mar 2026 | |||
| Dimension Capital I, L.P. | 8.1% | -6.7% | $107,152,737 | +$13,990,895 | 6,513,765 | +15% | Adam Goulburn | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 6.3% | +6.7% | $88,901,287 | +$21,850,000 | 5,085,886 | +33% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.5% | $34,360,615 | 4,637,060 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| TCG Crossover GP II, LLC | 5.5% | -24% | $80,795,199 | +$3,398,916 | 4,622,151 | +4.4% | Chen Yu | 31 Mar 2026 |
| BlackRock, Inc. | 6.3% | $20,045,661 | 3,840,165 | BlackRock, Inc. | 31 Dec 2024 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5.5% | $17,539,200 | 3,360,000 | SUVRETTA CAPITAL MANAGEMENT, LLC | 09 Apr 2025 | |||
| VANGUARD GROUP INC | 4.8% | -6% | $22,148,142 | -$1,240,441 | 2,988,953 | -5.3% | The Vanguard Group | 30 Sep 2025 |
| Versant Venture Capital VI, L.P. | 3.4% | -34% | $35,080,976 | -$17,220,640 | 2,236,708 | -33% | Versant Venture Capital VI, L.P. | 07 Jan 2026 |
| FMR LLC | 2.8% | $7,072,953 | 1,750,731 | FMR LLC | 30 May 2025 |
As of 31 Mar 2026, 187 institutional investors reported holding 86,940,802 shares of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE). This represents 103% of the company’s total 84,039,109 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9.2% | 7,692,298 | 0% | 7.2% | $126,538,302 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8% | 6,720,188 | +31% | 0.01% | $110,549,000 |
| BlackRock, Inc. | 6.7% | 5,637,684 | +35% | 0% | $92,739,901 |
| TCG Crossover Management, LLC | 5.5% | 4,622,151 | 0% | 2.2% | $76,034,384 |
| BVF INC/IL | 5.3% | 4,460,886 | +16% | 2.3% | $73,381,575 |
| BAKER BROS. ADVISORS LP | 5.2% | 4,345,736 | 0% | 0.41% | $71,487,357 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5% | 4,226,809 | +26% | 1.9% | $69,531,008 |
| Vestal Point Capital, LP | 4.3% | 3,603,465 | +365% | 1.7% | $59,276,999 |
| STATE STREET CORP | 4% | 3,353,980 | +59% | 0% | $55,172,971 |
| BRAIDWELL LP | 3.8% | 3,206,574 | +238% | 1.8% | $52,748,142 |
| Versant Venture Management, LLC | 3.8% | 3,180,780 | -27% | 37% | $52,323,831 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 3,100,245 | 0% | 0% | $50,999,030 |
| AMERICAN CENTURY COMPANIES INC | 3.3% | 2,809,647 | +111% | 0.02% | $46,218,693 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.4% | 2,002,040 | +95% | 3.9% | $32,933,558 |
| Aisling Capital Management LP | 1.9% | 1,555,664 | +5.7% | 5.4% | $25,590,673 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,540,812 | +28% | 0% | $25,352,784 |
| MARSHALL WACE, LLP | 1.7% | 1,433,152 | +259% | 0.03% | $23,575,351 |
| Bellevue Group AG | 1.5% | 1,250,000 | 0.49% | $20,562,500 | |
| MPM BIOIMPACT LLC | 1.4% | 1,176,928 | +0.3% | 1.5% | $19,360,466 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 1,041,372 | +83% | 0% | $17,124,824 |
| FMR LLC | 1.2% | 1,024,304 | -21% | 0% | $16,849,800 |
| GOLDMAN SACHS GROUP INC | 1.2% | 1,001,527 | +238% | 0% | $16,475,119 |
| Frazier Life Sciences Management, L.P. | 1.2% | 1,000,000 | 0.42% | $16,450,000 | |
| NORTHERN TRUST CORP | 0.98% | 826,624 | +19% | 0% | $13,597,964 |
| JANUS HENDERSON GROUP PLC | 0.82% | 685,926 | 0.01% | $11,293,772 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q1 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 86,940,802 | $1,430,092,919 | +$355,134,215 | $16.45 | 187 |
| 2025 Q4 | 64,479,520 | $1,011,015,664 | +$79,666,435 | $15.68 | 160 |
| 2025 Q3 | 60,027,627 | $444,802,878 | -$4,386,129 | $7.41 | 126 |
| 2025 Q2 | 62,196,889 | $280,514,086 | +$11,963,150 | $4.51 | 115 |
| 2025 Q1 | 59,523,717 | $276,191,314 | -$11,913,266 | $4.64 | 105 |
| 2024 Q4 | 60,988,332 | $423,262,031 | +$79,110,231 | $6.94 | 104 |
| 2024 Q3 | 49,754,753 | $263,674,421 | +$18,158,687 | $5.30 | 80 |
| 2024 Q2 | 45,836,316 | $171,427,053 | +$21,976,071 | $3.74 | 73 |
| 2024 Q1 | 39,892,581 | $281,249,822 | -$731,896 | $7.05 | 67 |
| 2023 Q4 | 40,102,427 | $226,575,690 | -$10,023,054 | $5.65 | 71 |
| 2023 Q3 | 42,042,126 | $201,382,486 | +$10,940,133 | $4.79 | 70 |
| 2023 Q2 | 39,734,743 | $272,184,520 | -$3,199,539 | $6.85 | 67 |
| 2023 Q1 | 39,769,032 | $309,801,540 | -$11,077,618 | $7.79 | 69 |
| 2022 Q4 | 41,325,746 | $314,458,629 | +$7,213,706 | $7.61 | 66 |
| 2022 Q3 | 40,353,101 | $329,604,037 | -$3,246,200 | $8.17 | 70 |
| 2022 Q2 | 38,778,221 | $374,994,819 | -$11,927,308 | $9.67 | 56 |
| 2022 Q1 | 39,943,480 | $559,876,587 | +$42,034,475 | $14.02 | 52 |
| 2021 Q4 | 36,340,047 | $741,974,000 | +$28,074,571 | $20.42 | 53 |
| 2021 Q3 | 34,892,057 | $759,420,127 | +$60,728,601 | $22.28 | 54 |
| 2021 Q2 | 32,095,195 | $705,074,000 | +$705,074,000 | $22.70 | 48 |